The Challenge Of Pricing Amgen's Newly Approved Prolia
Amgen's first-in-class drug Prolia is burdened with a high price point as it joins a competitive and price-sensitive market for osteoporosis drugs. But Amgen’s decision to value the drug at a premium, effectively sacrificing the first-line treatment market for osteoporosis, to maintain Prolia’s potential in oncology is telling. Certainly, pricing across multiple indications is becoming an increasing challenge for drugmakers, who are under growing scrutiny from payors even as they aim to push drugs to market quickly in one indication before expanding into other arenas. The issue becomes a particularly challenging tight rope to walk when as is true for Prolia one of the indications is in primary care and the other is in a high-priced specialty field such as oncology.
You may also be interested in...
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.
Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.